SG11201701311YA - Targeted delivery of tertiary amine-containing drug substances - Google Patents
Targeted delivery of tertiary amine-containing drug substancesInfo
- Publication number
- SG11201701311YA SG11201701311YA SG11201701311YA SG11201701311YA SG11201701311YA SG 11201701311Y A SG11201701311Y A SG 11201701311YA SG 11201701311Y A SG11201701311Y A SG 11201701311YA SG 11201701311Y A SG11201701311Y A SG 11201701311YA SG 11201701311Y A SG11201701311Y A SG 11201701311YA
- Authority
- SG
- Singapore
- Prior art keywords
- tertiary amine
- targeted delivery
- drug substances
- containing drug
- substances
- Prior art date
Links
- 229940088679 drug related substance Drugs 0.000 title 1
- 150000003512 tertiary amines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049206P | 2014-09-11 | 2014-09-11 | |
US201462087218P | 2014-12-03 | 2014-12-03 | |
US201462087755P | 2014-12-04 | 2014-12-04 | |
PCT/US2015/049494 WO2016040684A1 (en) | 2014-09-11 | 2015-09-10 | Targeted delivery of tertiary amine-containing drug substances |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701311YA true SG11201701311YA (en) | 2017-03-30 |
Family
ID=55459584
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202006504QA SG10202006504QA (en) | 2014-09-11 | 2015-09-10 | Targeted delivery of tertiary amine-containing drug substances |
SG11201701311YA SG11201701311YA (en) | 2014-09-11 | 2015-09-10 | Targeted delivery of tertiary amine-containing drug substances |
SG10202006505UA SG10202006505UA (en) | 2014-09-11 | 2015-09-10 | Targeted delivery of tertiary amine-containing drug substances |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202006504QA SG10202006504QA (en) | 2014-09-11 | 2015-09-10 | Targeted delivery of tertiary amine-containing drug substances |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202006505UA SG10202006505UA (en) | 2014-09-11 | 2015-09-10 | Targeted delivery of tertiary amine-containing drug substances |
Country Status (23)
Country | Link |
---|---|
US (1) | US20170247412A1 (en) |
EP (2) | EP3191502B1 (en) |
JP (5) | JP6473226B2 (en) |
KR (2) | KR20230172035A (en) |
CN (3) | CN114732916B (en) |
AU (3) | AU2015315007C1 (en) |
BR (1) | BR112017003975A2 (en) |
CA (1) | CA2959424C (en) |
CY (1) | CY1124606T1 (en) |
DK (1) | DK3191502T3 (en) |
EA (1) | EA201790521A1 (en) |
ES (1) | ES2886884T3 (en) |
HU (1) | HUE055539T2 (en) |
IL (2) | IL285102B2 (en) |
MX (3) | MX2017002313A (en) |
NZ (1) | NZ730552A (en) |
PL (1) | PL3191502T3 (en) |
PT (1) | PT3191502T (en) |
SG (3) | SG10202006504QA (en) |
SI (1) | SI3191502T1 (en) |
TW (5) | TWI813394B (en) |
WO (1) | WO2016040684A1 (en) |
ZA (1) | ZA201702169B (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX336540B (en) | 2010-06-08 | 2016-01-22 | Genentech Inc | Cysteine engineered antibodies and conjugates. |
KR101628872B1 (en) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | Compounds comprising self-immolative group |
AU2015315007C1 (en) * | 2014-09-11 | 2021-06-03 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
EP3191521A2 (en) | 2014-09-12 | 2017-07-19 | F. Hoffmann-La Roche AG | Cysteine engineered antibodies and conjugates |
CN107206101B (en) * | 2014-12-03 | 2021-06-25 | 基因泰克公司 | Quaternary ammonium compounds and antibody-drug conjugates thereof |
WO2017051254A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
WO2017051249A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
AU2016359230B2 (en) | 2015-11-25 | 2020-04-23 | Legochem Biosciences, Inc. | Conjugates comprising self-immolative groups and methods related thereto |
CN108136038A (en) | 2015-11-25 | 2018-06-08 | 乐高化学生物科学股份有限公司 | Conjugate and its correlation technique comprising peptide group |
US11173214B2 (en) | 2015-11-25 | 2021-11-16 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
CA3006000A1 (en) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
MA43835A (en) | 2016-03-25 | 2018-11-28 | Seattle Genetics Inc | PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINAL PRODUCTS AND THEIR INTERMEDIARIES |
KR20190005924A (en) * | 2016-05-10 | 2019-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | Antibody-drug conjugates of tuburicin analogs with improved stability |
BR112019001945A2 (en) | 2016-08-09 | 2019-05-07 | Seattle Genetics, Inc. | binder drug conjugate composition, pharmaceutically acceptable formulation, methods for treating a hyperproliferative disease or condition, for inhibiting the multiplication of a tumor cell or cancer cell, and for preparing a binder drug conjugate composition, and, compound |
KR20190074292A (en) * | 2016-10-18 | 2019-06-27 | 시애틀 지네틱스, 인크. | Targeted delivery of remedial pathway inhibitors of nicotinamide adenine dinucleotides |
WO2018124758A2 (en) * | 2016-12-28 | 2018-07-05 | 주식회사 인투셀 | Compound bearing beta-galactoside-introduced self-immolative linker |
KR102085798B1 (en) * | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | Compounds comprising beta-galactoside self-immolative linker |
CA3052837A1 (en) | 2017-02-28 | 2018-09-07 | Seattle Genetics, Inc. | Cysteine mutated antibodies for conjugation |
CN109790171B (en) | 2017-03-29 | 2022-07-26 | 乐高化学生物科学股份有限公司 | Pyrrolobenzodiazepine dimer precursors and ligand-linker conjugate compounds thereof |
BR112019022445A2 (en) * | 2017-04-27 | 2020-05-12 | Seattle Genetics, Inc. | COMPOSITION OF BINDER-DRUG CONJUGATE, FORMULATION, METHOD TO INHIBIT THE TUMOR CELL OR CANCER CELL MULTIPLICATION OR CAUSE APOPTOSIS IN A TUMOR OR CANCER CELL, AND, PHARMACEUTICAL CONNECTOR COMPOUND |
SG11202001543XA (en) * | 2017-09-08 | 2020-03-30 | Seattle Genetics Inc | Process for the preparation of tubulysins and intermediates thereof |
WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | Compounds compositions, and methods for the treatment of disease |
EP3746079A1 (en) * | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
AR114112A1 (en) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | GLIPICAN 3 ANTIBODIES AND CONJUGATES THEREOF |
AU2019240403A1 (en) | 2018-03-23 | 2020-10-08 | Seagen Inc. | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
US11827703B2 (en) | 2018-05-09 | 2023-11-28 | Legochem Biosciences, Inc. | Compositions and methods related to anti-CD19 antibody drug conjugates |
AU2019277094A1 (en) * | 2018-05-29 | 2021-01-21 | Bristol-Myers Squibb Company | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making |
EP4025233A4 (en) * | 2019-09-04 | 2023-07-12 | Seagen Inc. | Double-digestion assay for analyzing ligand-drug conjugates |
KR20210028544A (en) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use |
EP4153242B1 (en) | 2020-05-19 | 2024-05-15 | Les Laboratoires Servier | Para-amino-benzyl linkers, process for their preparation and their use in conjugates |
WO2021262910A2 (en) * | 2020-06-24 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
WO2022046941A1 (en) * | 2020-08-26 | 2022-03-03 | Angiex, Inc. | Antimitotic tetrapeptide-antibody conjugates and methods of using same |
EP4240415A1 (en) | 2020-11-08 | 2023-09-13 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
JP2024506300A (en) | 2021-02-03 | 2024-02-13 | シージェン インコーポレイテッド | Immune stimulating compounds and conjugates |
AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
JP2024520562A (en) | 2021-05-28 | 2024-05-24 | シージェン インコーポレイテッド | Anthracycline Antibody Conjugates |
TW202320857A (en) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | Linkers, drug linkers and conjugates thereof and methods of using the same |
WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
WO2023239803A1 (en) * | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
WO2024030577A1 (en) | 2022-08-03 | 2024-02-08 | Seagen Inc. | Immunostimulatory anti-pd-l1-drug conjugates |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US7238368B2 (en) * | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
ES2556641T3 (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR101438983B1 (en) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | Monomethylvaline compounds capable of conjugation to ligands |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP3498289A1 (en) | 2005-07-07 | 2019-06-19 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
AU2006294554B2 (en) | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
MX2008015132A (en) * | 2006-05-30 | 2008-12-10 | Genentech Inc | Antibodies and immunoconjugates and uses therefor. |
TWI412367B (en) * | 2006-12-28 | 2013-10-21 | Medarex Llc | Chemical linkers and cleavable substrates and conjugates thereof |
ES2649941T3 (en) * | 2007-02-23 | 2018-01-16 | Aileron Therapeutics, Inc. | Substituted amino acids to prepare triazole-linked macrocyclic peptides |
JP5727786B2 (en) | 2007-10-19 | 2015-06-03 | シアトル ジェネティクス,インコーポレーテッド | CD19 binding substance and use thereof |
PL2842575T3 (en) * | 2008-03-18 | 2018-02-28 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
SG189811A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
KR20140139480A (en) | 2011-12-05 | 2014-12-05 | 이제니카 바이오테라퓨틱스, 인크. | Antibody-drug conjugates and related compounds, compositions, and methods |
CN104379602B (en) * | 2012-03-08 | 2017-05-03 | 哈洛齐梅公司 | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2013173393A1 (en) * | 2012-05-15 | 2013-11-21 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
US9504756B2 (en) * | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
CN108465112B (en) * | 2012-05-15 | 2022-04-29 | 西雅图基因公司 | Self-stabilizing linker conjugates |
KR20160015227A (en) * | 2013-05-31 | 2016-02-12 | 제넨테크, 인크. | Anti-wall teichoic antibodies and conjugates |
KR20160015286A (en) * | 2013-05-31 | 2016-02-12 | 제넨테크, 인크. | Anti-wall teichoic antibodies and conjugates |
AU2015315007C1 (en) * | 2014-09-11 | 2021-06-03 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
CN107206101B (en) * | 2014-12-03 | 2021-06-25 | 基因泰克公司 | Quaternary ammonium compounds and antibody-drug conjugates thereof |
-
2015
- 2015-09-10 AU AU2015315007A patent/AU2015315007C1/en active Active
- 2015-09-10 EP EP15839347.0A patent/EP3191502B1/en active Active
- 2015-09-10 SI SI201531653T patent/SI3191502T1/en unknown
- 2015-09-10 SG SG10202006504QA patent/SG10202006504QA/en unknown
- 2015-09-10 ES ES15839347T patent/ES2886884T3/en active Active
- 2015-09-10 MX MX2017002313A patent/MX2017002313A/en unknown
- 2015-09-10 PL PL15839347T patent/PL3191502T3/en unknown
- 2015-09-10 CN CN202210393276.5A patent/CN114732916B/en active Active
- 2015-09-10 KR KR1020237042351A patent/KR20230172035A/en active Application Filing
- 2015-09-10 KR KR1020177008527A patent/KR20170053648A/en not_active Application Discontinuation
- 2015-09-10 CA CA2959424A patent/CA2959424C/en active Active
- 2015-09-10 EP EP21165610.3A patent/EP3900742B1/en active Active
- 2015-09-10 PT PT158393470T patent/PT3191502T/en unknown
- 2015-09-10 DK DK15839347.0T patent/DK3191502T3/en active
- 2015-09-10 CN CN202111053104.5A patent/CN113827737A/en active Pending
- 2015-09-10 BR BR112017003975-3A patent/BR112017003975A2/en active Search and Examination
- 2015-09-10 HU HUE15839347A patent/HUE055539T2/en unknown
- 2015-09-10 SG SG11201701311YA patent/SG11201701311YA/en unknown
- 2015-09-10 IL IL285102A patent/IL285102B2/en unknown
- 2015-09-10 CN CN201580061461.2A patent/CN107108694B/en active Active
- 2015-09-10 JP JP2017511189A patent/JP6473226B2/en active Active
- 2015-09-10 US US15/510,163 patent/US20170247412A1/en not_active Abandoned
- 2015-09-10 EA EA201790521A patent/EA201790521A1/en unknown
- 2015-09-10 NZ NZ730552A patent/NZ730552A/en unknown
- 2015-09-10 WO PCT/US2015/049494 patent/WO2016040684A1/en active Application Filing
- 2015-09-10 SG SG10202006505UA patent/SG10202006505UA/en unknown
- 2015-09-11 TW TW111127592A patent/TWI813394B/en active
- 2015-09-11 TW TW112127603A patent/TW202410924A/en unknown
- 2015-09-11 TW TW109123097A patent/TWI794617B/en active
- 2015-09-11 TW TW104130221A patent/TWI701049B/en active
- 2015-09-11 TW TW109123096A patent/TWI769478B/en active
-
2017
- 2017-02-21 MX MX2023000075A patent/MX2023000075A/en unknown
- 2017-02-21 MX MX2023000076A patent/MX2023000076A/en unknown
- 2017-02-26 IL IL250773A patent/IL250773B2/en unknown
- 2017-03-28 ZA ZA2017/02169A patent/ZA201702169B/en unknown
-
2018
- 2018-06-14 JP JP2018113739A patent/JP6824931B2/en active Active
-
2020
- 2020-02-10 JP JP2020020696A patent/JP2020090530A/en not_active Withdrawn
- 2020-10-20 AU AU2020257048A patent/AU2020257048A1/en not_active Abandoned
-
2021
- 2021-07-19 CY CY20211100646T patent/CY1124606T1/en unknown
-
2022
- 2022-03-16 JP JP2022041477A patent/JP2022069604A/en active Pending
- 2022-06-09 AU AU2022204013A patent/AU2022204013B2/en active Active
-
2023
- 2023-08-10 JP JP2023131605A patent/JP2023138841A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285102A (en) | Targeted delivery of tertiary amine-containing drug substances | |
HK1247878A1 (en) | Drug delivery device | |
HK1245071A1 (en) | Compositions for ileo-jejunal drug delivery | |
HK1247875A1 (en) | Drug delivery device | |
IL249777A0 (en) | Drug delivery device | |
HK1248626A1 (en) | Drug delivery device | |
DK3204876T3 (en) | Drug delivery device | |
IL250813A0 (en) | Drug delivery device | |
PL3171921T3 (en) | Drug delivery device | |
HK1246707A1 (en) | Drug delivery device | |
HK1216400A1 (en) | Therapeutic product delivery device | |
EP3023113A4 (en) | Disposable ductless drug delivery system | |
HK1244733A1 (en) | Drug delivery device | |
HUE052701T2 (en) | Drug delivery devices | |
HK1216399A1 (en) | Therapeutic product delivery device | |
EP3185940A4 (en) | Drug delivery apparatus | |
IL249789A0 (en) | Drug delivery device | |
GB201419540D0 (en) | Delivery of drugs | |
IL246874A0 (en) | Drug delivery system | |
GB201607778D0 (en) | Drug delivery device | |
HK1247871A1 (en) | Drug delivery device | |
HK1247870A1 (en) | Drug delivery device | |
GB2529249B (en) | Endoluminal drug delivery device | |
GB201410507D0 (en) | Drug delivery enhancement agents | |
IL250637A0 (en) | Targeted delivery of hydrophilic drugs |